D. Boral Capital Reiterates “Buy” Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $30.00 target price on the stock.

A number of other equities research analysts have also commented on IBRX. HC Wainwright started coverage on ImmunityBio in a research report on Thursday, March 6th. They issued a “buy” rating and a $8.00 price target for the company. BTIG Research started coverage on ImmunityBio in a research report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target for the company. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, ImmunityBio presently has an average rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Stock Down 1.0 %

Shares of NASDAQ:IBRX opened at $2.87 on Thursday. ImmunityBio has a twelve month low of $2.28 and a twelve month high of $10.53. The stock’s 50 day moving average is $3.08 and its 200-day moving average is $3.66. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of -3.12 and a beta of 0.82.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $8.74 million. Equities research analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Stephens Inc. AR bought a new position in ImmunityBio in the 4th quarter valued at $26,000. Captrust Financial Advisors bought a new position in ImmunityBio in the 3rd quarter valued at $41,000. Cibc World Markets Corp bought a new position in ImmunityBio in the 4th quarter valued at $35,000. Virtu Financial LLC bought a new position in ImmunityBio in the 3rd quarter valued at $51,000. Finally, Maia Wealth LLC bought a new position in ImmunityBio in the 4th quarter valued at $37,000. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.